Key facts
- This page summarizes Anne Vanlent's Form 4 filing for APPLIED GENETIC TECHNOLOGIES CORP.
- 7 reported transactions and 7 derivative rows are listed below.
- Accepted by SEC: 01 Dec 2022, 08:23.
Anne Vanlent - 30 Nov 2022 Form 4 Insider Report for APPLIED GENETIC TECHNOLOGIES CORP
- Reporting relationship
- Director
- Issuer ticker
- N/A
- Reported as of
- 30 Nov 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 01 Dec 2022, 08:23:04 UTC
- Prior SEC filing
- 01 Jul 2022
- Next SEC filing
- 03 Jan 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Stacie Aarestad, Attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Anne Vanlent filed Form 4 for APPLIED GENETIC TECHNOLOGIES CORP on 01 Dec 2022.
Change
- Previous filing in this sequence was filed on 01 Jul 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
AGTC
transaction
Derivative
Stock Option (Right to Buy)
Disposed to Issuer
- Transaction value
- Shares
- -16,000
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 30 Nov 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 16,000
- Exercise price
- $15.13
- Footnotes
- F1
AGTC
transaction
Derivative
Stock Option (Right to Buy)
Disposed to Issuer
- Transaction value
- Shares
- -8,000
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 30 Nov 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 8,000
- Exercise price
- $7.75
- Footnotes
- F1
AGTC
transaction
Derivative
Stock Option (Right to Buy)
Disposed to Issuer
- Transaction value
- Shares
- -10,000
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 30 Nov 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 10,000
- Exercise price
- $4.25
- Footnotes
- F1
AGTC
transaction
Derivative
Stock Option (Right to Buy)
Disposed to Issuer
- Transaction value
- Shares
- -10,000
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 30 Nov 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 10,000
- Exercise price
- $6.90
- Footnotes
- F1
AGTC
transaction
Derivative
Stock Option (Right to Buy)
Disposed to Issuer
- Transaction value
- Shares
- -10,000
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 30 Nov 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 10,000
- Exercise price
- $3.02
- Footnotes
- F1
AGTC
transaction
Derivative
Stock Option (Right to Buy)
Disposed to Issuer
- Transaction value
- Shares
- -12,000
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 30 Nov 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 12,000
- Exercise price
- $4.72
- Footnotes
- F1
AGTC
transaction
Derivative
Stock Option (Right to Buy)
Disposed to Issuer
- Transaction value
- Shares
- -14,000
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 30 Nov 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 14,000
- Exercise price
- $2.17
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Anne Vanlent is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 1 footnote
Footnote F1
At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option.
SEC remarks
Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 23, 2022, by and among Applied Genetic Technologies Corporation (the "Issuer"), Alliance Holdco Limited ("Parent") and Alliance Acquisition Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), on November 30, 2022, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger").